Beloranib BELO

An experimental weight-loss drug that blocked the body's fat-building process and led to major weight loss in human obesity trials, including one for a genetic condition called Prader-Willi syndrome. It was abandoned after several trial participants developed dangerous blood clots and some died, making it a stark example of a drug that worked but wasn't safe.

Also known as ZGN-433

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

3D Molecular Structure of C₂₉H₄₁NO₆

Drag to rotate · scroll to zoom

Chemistry

Formula: C29H41NO6
Molar mass: 499.6
CAS: 251111-30-5
PubChem CID: 6918502

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not approved; clinical development discontinued

Reported range Trial doses: 1.8-2.4 mg subcutaneous, twice weekly

Route Subcutaneous injection

Frequency Twice weekly (trial protocol)

Duration Trials ran several months before discontinuation

Clinical development was halted in 2016 after trial deaths linked to venous thromboembolism; not approved anywhere and should not be sourced from unregulated sellers.

Where this comes from Discontinued Phase III clinical trial data (Zafgen)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.